Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 39.21M.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 39.21M.
Subavaliada
O PE mais recente da empresa é -30.57, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 96.67M ações, um aumento de 9.67% em relação ao trimestre anterior.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.61.